1. Executive Summary (Confidence: High)

Cellvie, a spin-out from Harvard Medical School headquartered in Zürich, Switzerland, occupies a unique niche in the longevity and regenerative medicine sectors by focusing on "mitochondrial medicine".^[1] The organization is transitioning from a research-intensive startup to a clinical-stage biotechnology entity, driven by its proprietary Therapeutic Mitochondria Transplantation (TMT) platform.^[1] This technology, originally developed by Dr. James McCully, involves the transfer of healthy, viable mitochondria into cells where energy production has failed due to acute injury or aging.^[5] As of late 2025, Cellvie has secured approximately $16 million in cumulative funding, including a pivotal $5 million round in September 2025 led by Taiho Ventures to facilitate GMP-compliant manufacturing and the initiation of Phase I trials in kidney transplantation.^[2] The company’s strategic relocation to the Swiss biotech hub reflects its commitment to integrating with European healthcare networks while maintaining its foundational links to Boston’s elite medical ecosystem.^[1]